Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 7 for:    B-60 | Recruiting Studies

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04622319
Recruitment Status : Recruiting
First Posted : November 9, 2020
Last Update Posted : April 9, 2021
Sponsor:
Collaborators:
AstraZeneca
NSABP Foundation Inc
German Breast Group
Spanish Breast Cancer Research Group (SOLTI)
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : September 1, 2027